Literature DB >> 35812045

Trends in the risk of second primary malignances after non-Hodgkin's lymphoma.

Jingwen Li1, Fei Peng2, He Huang1, Zhen Cai1.   

Abstract

Patients with non-Hodgkin's lymphoma (NHL) have an increased risk of developing second primary malignances (SPMs). In the current study, we aimed to evaluate the trends and relative clinical variables of SPM risk among NHL survivors over the past four decades. Standardized incidence ratio (SIR) and cumulative incidence frequency (CIF) were assessed in patients diagnosed with first primary NHL between 1975-2016 from the Surveillance, Epidemiology, and End Results (SEER) database. As a result, the overall SIR was 1.13 for SPMs of all sites among NHL survivors. Risk factors included male patients, "other" races, chemotherapy and radiation, and younger age at the time of NHL diagnosis. The relative and cumulative risk for both hematological and solid second cancers after NHL increased over time, whereas the increasing trend was more remarkable for hematological malignances compared with solid tumors. For individual cancer sites, the trends of SIRs varied. A significantly increasing trend of SPM risk was observed in the group receiving chemotherapy and those younger than 40 years at the time of NHL diagnosis. Recent calendar years was not an independent risk factor after adjusting age, race, gender, and therapies in the multivariate Cox proportional hazard regression. To conclude, the current study showed that the relative and cumulative risk of developing SPMs significantly increased in patients diagnosed with NHL in recent years. The trend of SPM risk was associated with certain clinical and demographic variables, and might vary according to different cancer types. AJCR
Copyright © 2022.

Entities:  

Keywords:  Non-Hodgkin’s lymphoma; hematological second primary cancer; second malignant neoplasm; second primary malignancy; solid second primary cancer

Year:  2022        PMID: 35812045      PMCID: PMC9251676     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  32 in total

1.  Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Authors:  Michael Schaapveld; Berthe M P Aleman; Anna M van Eggermond; Cécile P M Janus; Augustinus D G Krol; Richard W M van der Maazen; Judith Roesink; John M M Raemaekers; Jan Paul de Boer; Josée M Zijlstra; Gustaaf W van Imhoff; Eefke J Petersen; Philip M P Poortmans; Max Beijert; Marnix L Lybeert; Ina Mulder; Otto Visser; Marieke W J Louwman; Inge M Krul; Pieternella J Lugtenburg; Flora E van Leeuwen
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

2.  Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time.

Authors:  A Foss Abrahamsen; A Andersen; O Nome; A B Jacobsen; H Holte; J Foss Abrahamsen; S Kvaløy
Journal:  Ann Oncol       Date:  2002-11       Impact factor: 32.976

3.  Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).

Authors:  Nadia Baras; Stefan Dahm; Jörg Haberland; Martin Janz; Katharina Emrich; Klaus Kraywinkel; Abdulgabar Salama
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

4.  The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.

Authors:  Jonathan D Tward; Merideth M M Wendland; Dennis C Shrieve; Aniko Szabo; David K Gaffney
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

5.  Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.

Authors:  Stephen K Gruschkus; David Lairson; J Kay Dunn; Jan Risser; Xianglin L Du
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

Review 6.  B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review.

Authors:  Eva Negri; D'Anna Little; Mauro Boiocchi; Carlo La Vecchia; Silvia Franceschi
Journal:  Int J Cancer       Date:  2004-08-10       Impact factor: 7.396

7.  Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort.

Authors:  Lucie M Turcotte; Qi Liu; Yutaka Yasui; Tara O Henderson; Todd M Gibson; Wendy Leisenring; Michael A Arnold; Rebecca M Howell; Daniel M Green; Gregory T Armstrong; Leslie L Robison; Joseph P Neglia
Journal:  J Clin Oncol       Date:  2019-10-17       Impact factor: 44.544

8.  Second primary malignancies after ocular adnexal lymphoma diagnosis.

Authors:  Asad Loya; Vignesh Ramachandran; Talha Ayaz; Christina Y Weng
Journal:  BMC Ophthalmol       Date:  2021-04-07       Impact factor: 2.209

9.  Malignancy Trends in HIV-Infected Patients Over the Past 10 Years in a Single-Center Retrospective Observational Study in the United States.

Authors:  Nancy Rihana; Sowmya Nanjappa; Cara Sullivan; Ana Paula Velez; Narach Tienchai; John N Greene
Journal:  Cancer Control       Date:  2018 Jan-Dec       Impact factor: 3.302

10.  Second neoplasms associated with primary cutaneous lymphomas.

Authors:  María Encarnación Gómez Sánchez; Maria Rodríguez Vázquez; Manuela Mollejo Villanueva
Journal:  An Bras Dermatol       Date:  2019-10-26       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.